Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Elara MD vs LillyDirect Foundayo

Elara MD
Graded #466

Lower grade

vs+13.700000000000003
LillyDirect Foundayo
Graded #165

Higher grade

The verdict

LillyDirect Foundayo takes it — 67.2/100 to 53.5/100.

LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLillyDirect Foundayo +32
40
72
Dose & formulationLillyDirect Foundayo +5
54
59
Clinical oversightLillyDirect Foundayo +15
63
78
Labs & monitoringEven
52
52
FulfillmentLillyDirect Foundayo +14
66
80
Contract termsEven
55
55
Elara MD · left barLillyDirect Foundayo · right bar

The numbers

MetricElara MDLillyDirect Foundayo
WeighScore53.5/10067.2/100
GradeCC
Scorecard rank#466#165
Semaglutide$249/mo (0.2 mg dose, compounded)Not disclosed
Tirzepatide$349/mo (2.0 mg dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Elara MD

Graded #466 · C

Strengths

  • Dose-banded monthly pricing published on-site ($249–$649/mo across tiers)
  • Both a semaglutide-range and a tirzepatide-range (GLP-1/GIP) option, plus microdosing
  • Medication included in the monthly price with free fast shipping when prescribed
  • Broad reach claimed (over 40 states)

Where it loses points

  • Molecules not named on-site (only 'Personalized GLP-1') — compounded status is inferred
  • No FDA compounded-medication disclaimer published
  • No named compounding pharmacy partner — prescriptions are patient-directed
  • LegitScript certification, medical director, and full state list not disclosed
  • Pricier than several compounded competitors
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard